Dot IO Health is Adelo’s in-house consulting firm — and the strategy engine behind every launch we support. Medical communications, HCP engagement strategy, and pharmaceutical launch execution, backed by the full Adelo intelligence platform.
We work alongside agencies. Not against them.
Fifteen years. Global top-20 pharma. Fast-growing biotechs. Data-connected launch strategies that most of the industry is only now catching up to. Dot IO Health is where the platform expertise meets the strategic experience.
We work alongside agencies. Not against them. If you’re a med comms agency and need strategic firepower on a specific brief, Dot IO Health is a resource you can call on — not a competing route to your client.
It isn’t the molecule. It rarely is. It’s the gap between what the clinical trial proves and what the commercial strategy assumes. Field strategies built on convention. Markets prioritised by relationships. Payer positioning built without community-level patient data.
Dot IO Health closes that gap. Every engagement we design is informed by Adelo’s intelligence platform — geomapping, session data, SDOH analysis, prescribing patterns — before we recommend anything. We don’t just tell you what the data says. We help you act on it.
Scientific narratives, publication strategy, and HCP education programmes built from real audience intelligence. We know what your HCPs are responding to — because we’ve been in the room and reading the signals.
Advisory board design, KOL mapping, speaker programme strategy. Every recommendation is grounded in Adelo session intelligence and geographic data — not instinct.
Payer positioning and commercial launch support built around SDOH-informed market analysis. We show you where the barriers actually are — before you find out during launch.
Market research, advisory board intelligence, and RWE support — faster, deeper, and more actionable than standard agency research, because it’s built on a real intelligence platform.
We automatically generate belief-based HCP personas from event engagement signals, translating them into targeted messaging, territory plans, and speaker strategies.
We start with your data — Adelo geomapping and SDOH analysis, your session archive, prescribing patterns, community health signals — before we make a single recommendation.
Programmes designed around what the intelligence tells us, not what worked on a different asset for a different company last year.
We deliver the programme, measure what changed, and feed the results back into the intelligence layer. Every engagement makes the next one better informed.
We work with the world’s largest pharmaceutical companies. We don’t name them publicly. But the work stands for itself.
Pre-Phase III readout mapping of community-level patient burden, SDOH barriers, and KOL landscape across the US, UK, and Europe. Informed payer positioning and commercial launch sequencing before the asset reached market.
Aligned local HCP engagement strategy with global brand direction across Canada, the US, and the UK. Advisory board design, KOL profiling, and data-informed territory planning across three markets simultaneously.
Biological sciences background. Career built across medical communications, HCP engagement, and data science-driven commercial strategy. Previously Group Director at WCG — launched the London office, grew the healthcare practice to $6M revenue across global clients. Before that, Interim Head of Healthcare at MS&L.
Serves on the Executive Committee of the Arrhythmia Alliance and Chairs its US Board of Directors, working to reduce sudden cardiac death and AF-related stroke.
Covers the commercial mechanics of health launches, why intelligence matters most in years 1–2, and how Dot IO Health uses Adelo’s platform to close the strategy-execution gap.
Name, email, and company required. One email only.
Dot IO Health is adelo’s in-house consulting firm and strategy engine behind every launch adelo supports. It covers medical communications, HCP engagement strategy and pharmaceutical launch execution, backed by the full adelo intelligence platform.
No. Dot IO Health works alongside agencies, not against them. If an agency needs strategic firepower on a specific brief, Dot IO Health is a resource to call on, not a competing route to the client.
It usually isn’t the molecule. It’s the gap between what the clinical trial proves and what the commercial strategy assumes, field strategies built on convention, markets prioritised by relationships, and payer positioning built without community-level patient data. Dot IO Health closes that gap using adelo’s geomapping, session data and SDOH analysis before recommending anything.
Five practice areas run on one intelligence platform: Medical Communications, HCP Engagement & KOL Strategy, Market Access & Launch Strategy, Research & Real-World Evidence, and Persona Intelligence & Session Analysis.
Three principles guide every engagement. Intelligence first, starting with adelo’s geomapping, SDOH analysis, session archive and prescribing patterns before any recommendation. Strategy from evidence, designing programmes around what the intelligence shows rather than what worked for a different asset last year. Measure and compound, feeding results from every engagement back into the intelligence layer so the next one is better informed.